Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence

Area of Science:

• Cardiovascular Research
• Oncology
• Nephrology

Background:

• Angiotensin II type 1 receptor antagonists (ARBs) are crucial for blood pressure management, renal, and cardiac protection, especially in patients intolerant to ACE inhibitors.
• Conflicting evidence exists regarding ARBs' impact on angiogenesis, with some studies suggesting tumor promotion and others indicating beneficial vascular effects.

Purpose of the Study:

• To review the angiogenic effects of ARBs in animal and cellular models of cardiovascular disease, stroke, and cancer.
• To explore the molecular mechanisms underlying ARB-mediated angiogenesis.
• To discuss the clinical implications of ARB use concerning vascular effects.

Main Methods:

• Review of existing literature on ARBs and angiogenesis in various disease models.
• Analysis of studies investigating molecular pathways involved in ARB-induced vascular changes.
• Synthesis of findings to evaluate clinical consequences.

Main Results:

• ARBs demonstrate predominantly anti-angiogenic effects in models of cancer and retinopathy.
• Conversely, ARBs have shown pro-angiogenic effects in myocardial infarction and stroke models, improving vascular density and recovery.
• Proposed mechanisms involve modulation of growth factors and signaling pathways.

Conclusions:

• The angiogenic effects of ARBs are context-dependent, varying significantly across different disease models.
• Understanding these dual effects is critical for optimizing ARB therapy and managing potential risks.
• Further research is needed to fully elucidate the clinical impact of ARB-mediated angiogenesis.